Safety of Levocetirizine During First Trimester of Pregnancy

Introduction to Safety Considerations

The American Academy of Allergy, Asthma, and Immunology recommends that levocetirizine should be avoided during the first trimester of pregnancy if possible, as there are limited safety data specifically for this medication 1, 2

The first trimester is the most critical time for concern about potential congenital malformations due to medication use, as this is when organogenesis occurs 3
While both first-generation and second-generation antihistamines generally have good safety records during pregnancy, there are limited specific data on levocetirizine use during the first trimester 1, 4

The British Association of Dermatologists suggests that if antihistamine treatment is necessary during pregnancy, chlorphenamine is often chosen by clinicians because of its long safety record 5
Cetirizine and loratadine are classified as FDA Pregnancy Category B drugs, indicating no evidence of harm to the fetus, and have more accumulated safety data than levocetirizine 6

The American College of Allergy, Asthma, and Immunology recommends considering non-pharmacological approaches first and preferring chlorphenamine, cetirizine, or loratadine over levocetirizine due to better documented safety profiles 1, 5, 6
Oral decongestants should be avoided during the first trimester due to conflicting reports of association with congenital malformations 1, 4
Combining decongestants with acetaminophen or salicylates may increase risk of malformations 4
Intranasal corticosteroids may be considered for nasal symptoms with a better safety profile than oral medications 7
Sodium cromolyn nasal spray is considered safe during pregnancy, though it requires frequent dosing 7

Benefit-risk assessment is crucial when treating pregnant women, and the potential benefit of symptom relief must be weighed against potential risks to the fetus 3, 4
Hydroxyzine should be specifically avoided during early pregnancy based on animal data showing potential risks 1, 2

Assuming all antihistamines have equivalent safety profiles during pregnancy is incorrect, as they do not 1, 6
Using oral decongestants during the first trimester should be avoided due to potential risks 4, 8

Diphenhydramine is a widely used antihistamine with generally good safety data, although older case-control studies suggest a possible association with cleft palate in the population exposed during the first trimester, with a strength of evidence considered low to moderate 9
Oral decongestants, such as phenylephrine and pseudoephedrine, are associated with conflicting reports of gastroschisis and small intestinal atresia during first trimester exposure, according to the American Academy of Allergy, Asthma, and Immunology, with a strength of evidence considered low 9

Intranasal corticosteroids, such as budesonide, may be used with a favorable safety profile during pregnancy, as recommended by the American College of Allergy, Asthma, and Immunology, with a strength of evidence considered moderate to high 9
Sodium cromolyn nasal spray is considered safe during pregnancy, with an FDA Pregnancy Category B classification, although it requires frequent dosing, as noted by the American Academy of Allergy, Asthma, and Immunology, with a strength of evidence considered moderate 9
Montelukast has an FDA Pregnancy Category B classification, with reassuring animal reproductive studies, according to the American College of Allergy, Asthma, and Immunology, with a strength of evidence considered moderate 9

Cetirizine and loratadine are recommended as the first‑line oral antihistamines for all trimesters of pregnancy because they have extensive safety records and are classified as FDA Pregnancy Category B, indicating no evidence of fetal harm in animal studies and reassuring human data. 10

Large observational cohort studies involving between 228 and 1,287,668 pregnancies have found no increased risk of major congenital malformations, spontaneous abortion, preterm birth, or low birth weight with cetirizine exposure (strength: high‑quality, population‑based data). 10
In first‑trimester exposure, major malformations occurred in only 2 of 41 live births, a rate comparable to background population rates, supporting the absence of teratogenic effect (strength: cohort data). 10

Hypertonic saline nasal irrigation is advised as the initial, non‑drug approach for pregnant patients with allergic rhinitis (strength: expert consensus). 10

If symptoms persist, intranasal budesonide may be added; budesonide is also FDA Pregnancy Category B, providing safe topical anti‑inflammatory control (strength: safety classification). 10
For inadequate response to antihistamines alone, combining cetirizine or loratadine with intranasal budesonide is recommended (strength: guideline‑based recommendation). 10
Montelukast can be considered in women who had a favorable response before pregnancy; it is classified as FDA Pregnancy Category B (strength: safety classification). 10

Oral decongestants such as phenylephrine and pseudoephedrine should be avoided during the first trimester because epidemiologic data associate them with gastroschisis and small‑intestinal atresia (strength: observational risk data). 10
Concurrent use of decongestants with acetaminophen or salicylates is discouraged, as combined exposure has been linked to an increased risk of fetal malformations (strength: observational risk data). 10